Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Haastrup, Eva ^a   Grau, Katrine ^b   Eugen Olsen, Jesper ^c   Thorball, Christian ^c   Kessing, Lars Vedel ^a   Ullum, Henrik ^a  

^a Rigshospitalet   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DANISH CITIZEN; DEPRESSION; DRUG USE; FEMALE; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROTEIN FUNCTION; REGISTER; RISK FACTOR; SEX DIFFERENCE; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DENMARK; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD DONORS; COHORT STUDIES; DENMARK; DEPRESSION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGISTRIES;

EID: 84908179389     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110555     Document Type: Article

References (49)

1. Anisman H, Merali Z. (1999) Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461: 199-233.
2. Anisman H, Merali Z. (2002) Cytokines, stress, and depressive illness. Brain Behav Immun 16: 513-524.
3. Dantzer R, Bluthe RM, Laye S, Bret-Dibat JL, Parnet P., et al. (1998) Cytokines and sickness behavior. Ann N Y Acad Sci 840: 586-590.
4. Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500: 399-411.
5. Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO & NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29: 287-291.
6. Maes M, Meltzer HY, Bosmans E, Bergmans R., Vandoolaeghe E, et al. (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 34: 301-309.
7. Miller AH, Maletic V, Raison C.L. (2009) Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biological Psychiatry 65: 732-741.
8. Raison CL, Capuron L, Miller A.H. (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31.
9. Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35: 298-306.
10. Pasco JA, Nicholson GC, Williams L.J., Jacka FN, Henry MJ, et al. (2010) Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 197: 372-377.
11. Matthews KA, Schott LL, Bromberger J, Cyranowski J., Everson-Rose SA, et al. (2007) Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition. Psychosom Med 69: 124-130.
12. Deverts DJ, Cohen S, DiLillo V.G., Lewis CE, Kiefe C, et al. (2010) Depressive symptoms, race, and circulating C-reactive protein: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Psychosom Med 72: 734-741.
13. Wium-Andersen M.K., Orsted DD, Nielsen S.F., Nordestgaard B.G. (2013) Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 70: 176-184.
14. Sennels HP, Jacobsen S, Jensen T., Hansen MS, Ostergaard M, et al. (2007) Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest 67: 821-835.
15. Macy EM, Hayes TE, Tracy R.P. (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43: 52-58.
16. Ockene IS, Matthews CE, Rifai N, Ridker P.M., Reed G., et al. (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47: 444-450.
17. Andersen O, Eugen-Olsen J, Kofoed K., Iversen J, Haugaard S.B. (2008) Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 80: 209-216.
18. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, et al. (2001) Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 59: 2054-2061.
19. Sier CF, Sidenius N, Mariani A., Aletti G, Agape V, et al (1999) Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79: 717-722.
20. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, et al. (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med.
21. Eugen-Olsen J., Andersen O, Linneberg A., Ladelund S, Hansen TW, et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268: 296-308.
22. Lyngbaek S, Sehestedt T, Marott J.L., Hansen TW, Olsen MH, et al. (2012) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol.
23. The Danish State Serum Institute S (2014) Medical product Statistics. Available: www.ssi.dk.
24. Kessing LV, Harhoff M, Andersen P.K. (2007) Treatment with antidepressants in patients with dementia-a nationwide register-based study. Int Psychogeriatr 19: 902-913.
25. Kessing LV, Harhoff M, Andersen P.K. (2008) Increased rate of treatment with antidepressants in patients with multiple sclerosis. Int Clin Psychopharmacol 23: 54-59.
26. Danner M, Kasl SV, Abramson J.L., Vaccarino V. (2003) Association between depression and elevated C-reactive protein. Psychosom Med 65: 347-356.
27. Elovainio M, Aalto AM, Kivimaki M, Pirkola S., Sundvall J, et al. (2009) Depression and C-reactive protein: population-based Health 2000 Study. Psychosom Med 71: 423-430.
28. Ford DE, Erlinger T.P. (2004) Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 164: 1010-1014.
29. Anderson RJ, Freedland KE, Clouse R.E., Lustman P.J. (2001) The Prevalence of Comorbid Depression in Adults With Diabetes: A meta-analysis. Diabetes Care 24: 1069-1078.
30. Musselman DL, Miller AH, Porter M.R., Manatunga A., Gao F, et al. (2001) Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary Findings. American Journal of Psychiatry 158: 1252-1257.
31. Musselman DL, Nemeroff C.B. (2000) Depression really does hurt your heart: stress, depression, and cardiovascular disease. Prog Brain Res 122: 43-59.
32. Raison CL, Miller A.H. (2003) Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 54: 283-294.
33. Nielsen NO, Strom M, Boyd H.A., Andersen EW, Wohlfahrt J, et al. (2013) Vitamin D status during pregnancy and the risk of subsequent postpartum depression: a case-control study. PLoS One 8: e80686. 10.1371/journal.-pone.0080686 [doi];PONE-D-13-23510 [pii].
34. Manderbacka K, Sund R, Koski S., Keskimaki I, Elovainio M. (2010) Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf.
35. Thielen K, Nygaard E, Andersen I., Rugulies R, Heinesen E, et al (2009) Misclassification and the use of register-based indicators for depression. Acta Psychiatr Scand 119: 312-319.
36. Langkilde AA, Hansen TW, Ladelund S, Linneberg A., Andersen O, et al. (2011) Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev.
37. Miller GE, Freedland KE, Carney R.M., Stetler CA, Banks W.A. (2003) Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun 17: 276-285.
38. Gariepy G, Wang J, Lesage A.D., Schmitz N. (2010) The longitudinal association from obesity to depression: results from the 12-year National Population Health Survey. Obesity (Silver Spring) 18: 1033-1038.
39. Edgren G, Tran TN, Hjalgrim H, Rostgaard K., Shanwell A, et al. (2007) Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion 47: 2017-2024.
40. Tuomainen TP, Salonen R, Nyyssonen K., Salonen J.T. (1997) Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 314: 793-794.
41. Langkilde A, Petersen J, Klausen H.H., Henriksen JH, Eugen-Olsen J, et al. (2012) Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One 7: e51698. 10.1371/journal.pone.0051698 [doi];PONE-D-12-21779 [pii].
42. Andersen AB, Law I, Ostrowski S.R., Lebech AM, Hoyer-Hansen G, et al. (2006) Self-reported fatigue common among optimally treated HIV patients: no correlation with cerebral FDG-PET scanning abnormalities. Neuroimmunomo-dulation 13: 69-75.
43. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J., Pedersen BK, et al. (2005) High Plasma Levels of Intact and Cleaved Soluble Urokinase Receptor Reflect Immune Activation and Are Independent Predictors of Mortality in HIV-1-Infected Patients. J Acquir Immune Defic Syndr 39: 23-31.
44. Cinque P, Nebuloni M, Santovito M.L., Price RW, Gisslen M, et al. (2004) The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 55: 687-694.
45. Deininger MH, Trautmann K, Magdolen V., Luther T, Schluesener HJ, et al (2002) Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor. Neurosci Lett 324: 80-82.
46. Fauser S, Deininger MH, Kremsner P.G., Magdolen V., Luther T, et al. (2000) Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria. J Neuroimmunol 111: 234-240.
47. Gveric D, Hanemaaijer R, Newcombe J., van Lent NA, Sier CF, et al. (2001) Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124: 1978-1988.
48. Walker DG, Lue LF, Beach T.G. (2002) Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res 926: 69-79.
49. Cunningham O, Campion S, Perry V.H., Murray C., Sidenius N, et al. (2009) Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia 57: 1802-1814.